SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ALTAREX CORP. (TSE: AXO)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (229)5/15/2000 7:46:00 PM
From: DaveAu  Read Replies (1) of 274
 
Stefaan,

I think your link is wrong. It should be

antisoma.co.uk

I'll try to take a closer look at that on the weekend. Based on your profile, I would expect you would have a better understanding then most of us about the science involved. Are they targeting the same stage as Altarex (late stage following chemo) ? Is it possible that the products might be used together? I know Altarex is developing a second antibody also targeted at Ovarian cancer which I believe they intend to be used in conjunction with Ovarex Mab. Their scientific advisory board recommended this multi-antibody approach.

For what it's worth, here's an excerpt from Altarex's prospectus that mentions the competition including Antisoma:


Based on its review of the industry, the Company is not aware of any other company that is
focusing on AIT © Technology. There are a number of companies however, that focus on the broader use of
antibodies to treat various diseases. These companies include Coulter Pharmaceuticals Inc., Genentech,
IDEC, Medarex Inc. and Antisoma plc among others. The Company expects that its platform AIT ©
Technology will attract significant additional competitors over time. In order to compete successfully, the
Company's goal is to develop proprietary positions in patented drugs for therapeutic markets which have not
been satisfactorily addressed by conventional research strategies and, in the process, extend its expertise in
biopharmaceutical product design.


Dave
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News